ProfileGDS5678 / 1428648_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 88% 89% 88% 86% 86% 85% 88% 87% 88% 88% 88% 89% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5424486
GSM967853U87-EV human glioblastoma xenograft - Control 26.903588
GSM967854U87-EV human glioblastoma xenograft - Control 37.0804189
GSM967855U87-EV human glioblastoma xenograft - Control 47.1018588
GSM967856U87-EV human glioblastoma xenograft - Control 56.6369686
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3184986
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1951185
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8374688
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7285487
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8906688
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8326288
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9747588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9555389
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.896388